Near-term prospects for gene therapy

Near-term prospects for gene therapy Despite increasing attention to the potential of in vivo gene therapies, the near-term opportunities will continue to be ex vivo autologous treatments, according to executives at Somatix Therapy Corp.

"It's like bone marrow transplantation," said David Carter, president and CEO, in a meeting with BioCentury. "I think it's an effective business and that's how it will be regulated."...